KDM3B enforces a non-mutational ErbB signaling state that sustains cholangiocarcinoma
KDM3B enforces a non-mutational ErbB signaling state that sustains cholangiocarcinoma
Andersen, J. B.; Luo, Y.; Nousias, O.; Zhuravleva, E.; Lafuente-Barquero, J.; Nepal, C.; Marino, A.; Yangngam, S.; Taranta, A.; Colaco, A. R.; Lu, S.; Wierer, M.; O'Rourke, C. J.
AbstractMore than 50% of cholangiocarcinoma (CCA) patients lack druggable mutations, showing broad non-mutational epigenetic perturbations, whose mechanistic insights and clinical benefit remain largely unexplored. Across multiple CCA patient cohorts, we identified prevalent significant upregulation of lysine demethylase (KDM) gene families, with KDM3B emerging as a critical epigenetic dependency for sustaining tumor fitness. KDM3B loss reduced colony formation, proliferation, and migration across intra- and extrahepatic CCA tumor models. Integrated multi-omics linked KDM3B to ErbB activation and downstream PI3K-AKT oncogenic signaling. Mechanistically, KDM3B is bound to the ERBB3 promoter, removing repressive H3K9me2 marks to transcriptionally activate ERBB3, augmenting ErbB receptor activity. Spatial and single cell transcriptomics from patient tumors revealed that high KDM3B-ERBB3 coupling reshapes the tumor niche via enhancing the epithelial-mesenchymal transition crosstalk with neighborhood cells to establish a pro-invasive microenvironment. Pharmacologic inhibition in vivo of the KDM3B downstream ERBB-Akt regulatory axis suppressed CCA xenograft tumor growth. These findings establish KDM3B as a non-mutational epigenetic activator of ErbB-driven signaling, reshaping the tumor ecosystem, and defining the KDM3B-ErbB axis as a vulnerability in CCA.